Search results for "Neoplasms"

showing 10 items of 7988 documents

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

2017

IF 1.590; International audience; Background: The tumor spectrum in the Lynch syndrome is well defined, comprising an increased risk of developing colonic and extracolonic malignancies. Muir-Torre syndrome is a variant with a higher risk of skin disease. Patients have been described carrying mutations in the mismatch repair genes and presenting tumors with unusual histology or affected organ not part of the Lynch syndrome spectrum. Hence, the real link between Lynch syndrome, or Muir-Torre syndrome, and these tumors remains difficult to assess.Case presentation: We present the case of a 45-year-old-woman, diagnosed with breast cancer at 39 years of age and skin squamous cell carcinoma (SCC)…

0301 basic medicinePathologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitieslcsh:QH426-470Case Report[SDV.CAN]Life Sciences [q-bio]/CancerMLH1lcsh:RC254-282Sebaceous adenoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineSebaceous adenomaBreast cancerMuir–Torre syndromeSquamous cell carcinomaPMS2Skin Squamous Cell CarcinomaMedicineneoplasmsGenetics (clinical)MSIbusiness.industryMicrosatellite instabilitynutritional and metabolic diseasesMuir-Torre syndromeMSI-Llcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMMRLynch syndromedigestive system diseases3. Good healthMSH2lcsh:Genetics030104 developmental biologyLynch syndromeOncologyMSH2030220 oncology & carcinogenesisCancer researchbusiness
researchProduct

Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT)

2017

Abstract Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) is a rare benign lesion characterized by slow growth, infiltrative behavior and high rate of local recurrences. Only one case has been described in retroperitoneum, at renal hilum, but not involving pelvis or parenchyma. Here we present the first case of PHAT arising in the renal parenchyma. A nodular lesion in right kidney lower pole was diagnosed to a 61 year old woman. The patient underwent right nephrectomy. Microscopically, the lesion showed solid and pseudo-cystic components with hemorrhagic areas characterized by aggregates of ectatic blood vessels. Pleomorphic cells were characterized by large eosinophilic cytoplasm with irre…

0301 basic medicinePathologymedicine.medical_specialtymedicine.medical_treatment2734Pleomorphic Hyalinizing Angiectatic Tumor (PHAT)Renal tumorKidneyRenal hilumNephrectomyPathology and Forensic MedicineLesion03 medical and health sciences0302 clinical medicineEctasiaParenchymaEosinophilicmedicineHumansPartial nephrectomyKidneybusiness.industryKidney NeoplasmCell BiologyMiddle AgedKidney NeoplasmsNephrectomyTreatment Outcome030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.symptombusinessHumanPathology - Research and Practice
researchProduct

MiR-675-5p supports hypoxia induced epithelial to mesenchymal transition in colon cancer cells

2017

// Viviana Costa 1, * , Alessia Lo Dico 2, * , Aroldo Rizzo 3 , Francesca Rajata 3 , Marco Tripodi 4, 5 , Riccardo Alessandro 6, 7, * , Alice Conigliaro 4, * 1 Innovative Technological Platforms for Tissue Engineering, Theranostic and Oncology, Rizzoli Orthopedic Institute, Palermo, Italy 2 Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milano, Italy 3 Unita Operativa di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti “Villa Sofia-Cervello”, Palermo, Italy 4 Dipartimento di Biotecnologie Cellulari ed Ematologia, Sapienza University of Rome, Rome, Italy 5 National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy 6 Dipartimen…

0301 basic medicinePathologymedicine.medical_specialtymiRNA675Epithelial-Mesenchymal TransitionTranscription GeneticColorectal cancerDown-RegulationMetastasiMetastasis03 medical and health sciences0302 clinical medicineGliomaCell Line TumormedicinemetastasisHumansEpithelial–mesenchymal transitionNeoplasm MetastasisLymph nodeMetastatic colon cancerCRC; EMT; Hypoxia; Metastasis; MiRNA675; Oncologybusiness.industryhypoxiaEMTHypoxia (medical)medicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaCRCTransplantationDNA-Binding ProteinsMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic NeoplasmsCancer researchmedicine.symptombusinessResearch Paper
researchProduct

Guidelines are silver, but a multidisciplinary team discussion may be golden?

2018

0301 basic medicinePatient Care TeamMedical educationCarcinoma HepatocellularSilverHepatologybusiness.industryLiver NeoplasmsMultidisciplinary teamCombined Modality Therapy03 medical and health sciences030104 developmental biology0302 clinical medicineMedicineHumans030211 gastroenterology & hepatologybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Pharmacogenomics of Scopoletin in Tumor Cells

2016

Drug resistance and the severe side effects of chemotherapy necessitate the development of novel anticancer drugs. Natural products are a valuable source for drug development. Scopoletin is a coumarin compound, which can be found in several Artemisia species and other plant genera. Microarray-based RNA expression profiling of the NCI cell line panel showed that cellular response of scopoletin did not correlate to the expression of ATP-binding cassette (ABC) transporters as classical drug resistance mechanisms (ABCB1, ABCB5, ABCC1, ABCG2). This was also true for the expression of the oncogene EGFR and the mutational status of the tumor suppressor gene, TP53. However, mutations in the RAS onc…

0301 basic medicinePharmaceutical ScienceATP-binding cassette transporterDrug resistancePharmacologycoumarinAnalytical Chemistrychemistry.chemical_compound0302 clinical medicineNeoplasmsDrug DiscoveryABC-transportermicroarraysNF-kappa BABCB5Drug Resistance MultipleGene Expression Regulation NeoplasticMolecular Docking SimulationDrug developmentChemistry (miscellaneous)030220 oncology & carcinogenesisherbal medicineMolecular MedicineSignal TransductionTumor suppressor geneProtein Array AnalysisBiologyArticlelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistrymultidrug resistanceCell Line TumorScopoletinHumansPhysical and Theoretical ChemistryTranscription factorScopoletinOncogenePlant ExtractsOrganic ChemistryTranscription Factor RelAphytotherapy030104 developmental biologyArtemisiachemistryDrug Resistance NeoplasmPharmacogeneticsCancer researchABC-transporter; cluster analysis; coumarin; herbal medicine; microarrays; multidrug resistance; phytotherapyATP-Binding Cassette Transporterscluster analysisMolecules
researchProduct

Chemoresistance and chemosensitization in cholangiocarcinoma

2017

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern onco…

0301 basic medicinePharmacologybile ductschemotherapydrug delivery systems0302 clinical medicineChemosensitizationantineoplastic agentsmolecular biologyReceptorhumansreceptor protein-tyrosine kinasesmedia_commonapoptosisgene expression regulationbile duct neoplasmsDrug Resistance Multipletargeted therapiesGene Expression Regulation Neoplasticmultiplebiliary cancer; chemotherapy; liver cancer; multidrug resistance; targeted therapies; antineoplastic agents; apoptosis; bile duct neoplasms; bile ducts; cell survival; cholangiocarcinoma; drug delivery systems; drug resistance multiple; drug resistance; neoplasm; epithelial cells; gene expression regulation neoplastic; genetic therapy; humans; protein kinase inhibitors; receptor protein-tyrosine kinases; signal transduction; treatment outcome; molecular medicine; molecular biology030220 oncology & carcinogenesisHepatocellular carcinomabiliary cancerLiver cancercholangiocarcinomaTyrosine kinasesignal transductionDrugHepatoblastomamedia_common.quotation_subjectcell survivalPharmacological treatmentliver cancer03 medical and health sciencesmultidrug resistancemedicinemolecular medicinedrug resistancebusiness.industrymedicine.diseaseepithelial cellsneoplasticprotein kinase inhibitors030104 developmental biologyDrug Resistance NeoplasmCancer researchtreatment outcomebusinessneoplasmgenetic therapy
researchProduct

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

2018

Although many anticancer agents for gastric cancer have been developed, the prognosis for many patients remains poor. Recently, costimulatory immune molecules that reactivate antitumor immune responses by utilizing the host immune system have attracted attention as new therapeutic strategies. CD137 is a costimulatory molecule that reportedly potentiates the antitumor activity of tumor-targeting monoclonal antibodies (mAbs) by enhancing antibody-dependent cellular cytotoxicity. However, it remains unclear whether CD137 stimulates tumor-regulatory activity in gastric cancer. In this study, we investigated the antitumor effects of CD137 stimulation on gastric cancer cells administered tumor-ta…

0301 basic medicinePhysiologyCytotoxicityCancer Treatmentlcsh:MedicineNK cellsToxicologyPathology and Laboratory MedicineAntineoplastic Agents ImmunologicalSpectrum Analysis Techniques0302 clinical medicineImmune PhysiologyCellular typeslcsh:ScienceInnate Immune SystemCytotoxicity AssayMultidisciplinarybiologyChemistryImmune cellsCD137Drug SynergismFlow CytometryRecombinant ProteinsUp-RegulationGene Expression Regulation NeoplasticKiller Cells NaturalOncologySpectrophotometry030220 oncology & carcinogenesisCytokinesWhite blood cellsFemaleTumor necrosis factor alphaCytophotometryAntibodyResearch ArticleCell biologyBlood cellsCell Survivalmedicine.drug_classImmunologyAntibodies Monoclonal HumanizedResearch and Analysis MethodsMonoclonal antibody03 medical and health sciencesImmune systemStomach NeoplasmsCell Line TumorGastrointestinal TumorsmedicineHumansSecretionCell ProliferationMedicine and health sciencesBiology and life scienceslcsh:RCancers and NeoplasmsCancerTrastuzumabMolecular Developmentmedicine.diseaseGranzyme BGastric Cancer4-1BB Ligand030104 developmental biologyAnimal cellsImmune SystemCancer cellCancer researchbiology.proteinlcsh:QPhysiological ProcessesDevelopmental BiologyPLOS ONE
researchProduct

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017

Summary Most patients with advanced triple-negative breast cancer (TNBC) develop drug resistance. MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant chemotherapy. Herein, we demonstrate that MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells (CSCs) in TNBC. MYC and MCL1 increased mitochondrial oxidative phosphorylation (mtOXPHOS) and the generation of reactive oxygen species (ROS), processes involved in maintenance of CSCs. A mutant of MCL1 that cannot localize in mitochondria reduced mtOXPHOS, ROS levels, and drug-resistant CSCs without affecting the anti-apoptotic function of MCL1. Increased levels of ROS, a by-product of a…

0301 basic medicinePhysiologyMice NudeTriple Negative Breast NeoplasmsOxidative phosphorylationTumor initiationMitochondrionBiologyOxidative PhosphorylationArticleProto-Oncogene Proteins c-myc03 medical and health sciencesCancer stem cellCell Line TumorAnimalsHumansMCL1Molecular BiologyTriple-negative breast cancerchemistry.chemical_classificationReactive oxygen speciesCell BiologyMitochondria030104 developmental biologychemistryDrug Resistance NeoplasmNeoplastic Stem CellsCancer researchMyeloid Cell Leukemia Sequence 1 ProteinFemaleStem cellReactive Oxygen SpeciesCell Metabolism
researchProduct

Modulating tumor hypoxia by nanomedicine for effective cancer therapy

2016

Hypoxia, a characteristic feature of tumors, is indispensable to tumor angiogenesis, metastasis, and multi drug resistance. Hypoxic avascular regions, deeply embedded inside the tumors significantly hinder delivery of therapeutic agents. The low oxygen tension results in resistance to the current applied anti-cancer therapeutics including radiotherapy, chemotherapy, and photodynamic therapy, the efficacy of which is firmly tied to the level of tumor oxygen supply. However, emerging data indicate that nanocarriers/nanodrugs can offer substantial benefits to improve the efficacy of current therapeutics, through modulation of tumor hypoxia. This review aims to introduce the most recent advance…

0301 basic medicinePhysiologymedicine.medical_treatmentClinical BiochemistryPhotodynamic therapy02 engineering and technologyPharmacologyBiologyMetastasis03 medical and health sciencesNeoplasmsmedicineHumansDrug CarriersNeovascularization PathologicTumor hypoxiaCell BiologyTumor OxygenationHypoxia (medical)021001 nanoscience & nanotechnologymedicine.diseaseCell HypoxiaNanostructuresOxygenRadiation therapyNanomedicine030104 developmental biologyTumor HypoxiaNanomedicinemedicine.symptomNanocarriers0210 nano-technologyJournal of Cellular Physiology
researchProduct

Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy

2017

Natural polyphenols are organic chemicals which contain phenol units in their structures. They show antitumor properties. However, a key problem is their short half-life and low bioavailability under in vivo conditions. Still, definitively demonstrating the human benefits of isolated polyphenolic compounds (alone or in combination) using modern scientific methodology has proved challenging. The most common discrepancy between experimental and clinical observations is the use of nonphysiologically relevant concentrations of polyphenols in mechanistic studies. Thus, it remains highly controversial how applicable underlying mechanisms are with bioavailable concentrations and biological half-li…

0301 basic medicinePhytochemicalsBiological AvailabilityPharmacology03 medical and health sciencesDrug Delivery Systems0302 clinical medicineIn vivoNeoplasmsDrug DiscoveryAnimalsAnticarcinogenic AgentsHumansAnticarcinogenic AgentsCancer preventionOrganic chemicalsChemistryPolyphenolsfood and beveragesAntineoplastic Agents PhytogenicBioavailability030104 developmental biologyPolyphenol030220 oncology & carcinogenesisMolecular MedicineBiological availabilityJournal of Medicinal Chemistry
researchProduct